文献速递甲状腺疾病

碘化钾使用与甲状腺危象患者结局:一项观察性研究

Potassium Iodide Use and Patient Outcomes for Thyroid Storm: An Observational Study.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

基于日本诊断程序组合数据库2010年7月至2022年3月住院的甲状腺危象患者,比较入院2天内使用碘化钾(KI组)与未使用(非KI组)的院内死亡、住院天数和总费用。3188例中2350例使用KI,校正混杂后KI使用与院内死亡无显著关联(OR 0.91,95%CI 0.62-1.34);在Graves病患者中KI组院内死亡较低(OR 0.46,95%CI 0.25-0.88)。作者认为KI可能降低Graves病甲状腺危象患者的院内死亡。

要点

  • 甲状腺危象住院患者中,校正混杂后早期使用KI与院内死亡无显著关联(OR 0.91,95%CI 0.62-1.34)。
  • 在Graves病患者中,KI组院内死亡低于非KI组(OR 0.46,95%CI 0.25-0.88)。
  • KI组住院天数更短(亚分布风险比1.15,95%CI 1.05-1.27),总住院费用更低(OR 0.92,95%CI 0.85-1.00)。

核心结论

  • 作者认为KI可能降低Graves病甲状腺危象住院患者的院内死亡。

研究设计与样本

  • 使用日本诊断程序组合数据库的观察性研究,纳入2010年7月至2022年3月住院的甲状腺危象患者3188例。
  • 比较入院2天内接受KI(KI组,2350例)与未接受KI(非KI组,838例)的患者结局。
  • 预设按是否诊断Graves病进行亚组分析。

主要发现

  • KI组粗院内死亡率为6.1%(143/2350),非KI组为7.8%(65/838)。
  • 校正潜在混杂因素后,KI使用与院内死亡无显著关联(OR 0.91,95%CI 0.62-1.34)。
  • 在诊断Graves病的患者中,KI组院内死亡低于非KI组(OR 0.46,95%CI 0.25-0.88)。
  • 在未诊断Graves病的患者中,KI组与非KI组院内死亡无显著差异(OR 1.11,95%CI 0.67-1.85)。
  • KI组较非KI组住院天数更短(亚分布风险比1.15,95%CI 1.05-1.27),总住院费用更低(OR 0.92,95%CI 0.85-1.00)。

关键数值与推荐

  • 部分临床指南推荐碘联合抗甲状腺药物作为甲状腺危象的初始药物治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Iodine, combined with antithyroid drugs, is recommended as an initial pharmacologic treatment for thyroid storm according to some clinical guidelines. However, the clinical efficacy of iodine in managing thyroid storm remains unexplored. OBJECTIVE: This study aimed to determine whether early potassium iodide (KI) use is associated with mortality in patients hospitalized for thyroid storm. METHODS: Using the Japanese Diagnosis Procedure Combination database, we identified patients hospitalized with thyroid storm between July 2010 and March 2022. We compared in-hospital mortality, length of stay, and total hospitalization costs between patients who received KI within 2 days of admission (KI group) vs those who did not (non-KI group). Prespecified subgroup analyses were performed based on the presence of the diagnosis of Graves' disease. RESULTS: Among 3188 eligible patients, 2350 received KI within 2 days of admission. The crude in-hospital mortality was 6.1% (143/2350) in the KI group and 7.8% (65/838) in the non-KI group. After adjusting for potential confounders, KI use was not significantly associated with in-hospital mortality (odds ratio [OR] for KI use, 0.91; 95% CI, 0.62-1.34). In patients with the diagnosis of Graves' disease, in-hospital mortality was lower in the KI group than in the non-KI group (OR, 0.46; 95% CI, 0.25-0.88). No significant difference in in-hospital mortality was observed in patients without the diagnosis of Graves' disease (OR, 1.11; 95% CI, 0.67-1.85). Length of stay was shorter (subdistribution hazard ratio, 1.15; 95% CI, 1.05-1.27), and total hospitalization costs were lower (OR, 0.92; 95% CI, 0.85-1.00) in the KI group compared with the non-KI group. CONCLUSION: Our findings suggest that KI may reduce in-hospital mortality among patients hospitalized for thyroid storm with Graves' disease.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Matsuo Y, Miyawaki A, Watanabe H, et al. Potassium Iodide Use and Patient Outcomes for Thyroid Storm: An Observational Study. J Clin Endocrinol Metab. 2025. PMID: 38546426. doi:10.1210/clinem/dgae187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。